P76.61 Long Follow up Study of Comparing Erlotinib (ER) with Gefitinib (GE) for Previously Treated Advanced Non-Small Cell Lung Cancer: WJOG5108LFS

We reported the results of randomized phase III study comparing GE with ER when they were administered in patients (pts) with previously treated advanced lung adenocarcinoma (WJOG 5108L) in 2016. The data cutoff date of the study was Oct. 28, 2013 and progression free survival time was confirmed in each treatment group. However, confirmation of final overall survival (OS) was not completed because of short follow-up time. Therefore, we conducted a new protocol study, WJOG5108LFS, which followed up the survival of same pts entered on the previous study.